Hepatitis D Review: Challenges for the Resource-Poor Setting

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis D virus (HDV) is the most severe human viral infection, necessitating hepatitis B surface antigen (HBsAg) for replication.
• HDV affects 10-70 million people, with elimination closely linked to hepatitis B virus (HBV) control.
• Limited data exists in resource-poor settings, and treatment options for HDV have historically been scarce and inaccessible.

Purpose of the Study:

• To review the current landscape of Hepatitis D treatment options.
• To highlight recent therapeutic advancements and their implications.
• To address the challenges of accessibility in resource-limited areas.

Main Methods:

• Review of existing literature on HDV epidemiology and treatment.
• Analysis of recent clinical trial data for novel HDV therapeutics.
• Discussion of treatment guidelines and access barriers.

Main Results:

• Pegylated interferon alpha (Peg IFN α) has shown limited efficacy (20% response rate).
• Bulevirtide (Hepcludex®), an entry inhibitor, is approved in Europe, showing >50% response rates when combined with Peg IFN α and/or nucleos(t)ide analogues.
• Emerging therapies include lonafarnib, nucleic acid polymers, and Peg IFN lambda (λ), with promising outcomes and tolerability.

Conclusions:

• New specific therapies for Hepatitis D, like bulevirtide, represent a significant advancement over previous treatments.
• Despite promising results, access to these novel agents is significantly delayed in resource-limited regions.
• Facilitating access to care for vulnerable populations affected by HDV is a critical unmet need requiring stakeholder collaboration.